3
Announcements
Trials
Browse
Landscape
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Observational
1
Sponsor
Cancer Type
Sarcoma
1
Dermatologic
1
Conditions
Skin Neoplasms
3
Carcinoma, Basal Cell
3
Dermatofibrosarcoma
2
Surgical Wound
1
Nonmelanoma Skin Cancer
1
Neoplasms, Adnexal and Skin Appendage
1
Melanoma
1
Histiocytoma, Malignant Fibrous
1
Cicatrix
1
Carcinoma, Squamous Cell
1
Interventions
Ipilimumab
114
pembrolizumab
95
Nivolumab
91
aldesleukin
86
Interleukin-2
57
Cyclophosphamide
54
Dacarbazine
52
Vemurafenib
39
trametinib
37
Temozolomide
37
incomplete Freund's adjuvant
35
fludarabine phosphate
35
sargramostim
32
dabrafenib
32
fludarabine
26
Bevacizumab
26
Paclitaxel
22
MART-1 Antigen
21
Granulocyte-Macrophage Colony-Stimulating Factor
21
montanide ISA 51
20
Interferon-alpha
20
Cisplatin
20
Carboplatin
19
Sorafenib
18
Introns
17
Biopsy
17
cobimetinib
16
Radiosurgery
16
atezolizumab
15
Radiotherapy
15
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Melanoma
×
Mohs Surgery
×
Clear all
NCT02310503
2020-05-05
REGESMOHS
Fundación Academia Española de Dermatología
Completed
6,000 enrolled